Interviews

In an interview with Targeted Oncology, Hope S. Rugo, MD, FASCO, discussed data from the ELEVATE trial of elacestrant combinations in ER-positive/HER2-negative metastatic breast cancer.

Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discussed the real-world effectiveness of brexu-cel for relapsed/refractory B-cell acute lymphocytic leukemia.

In an interview with Targeted Oncology, Aristotelis Tsirigos, PhD, discussed a study evaluating a self-taught artificial intelligence tool that can accurately diagnose cases of adenocarcinoma.

Bhavana Pothuri, MD, discusses the biggest unmet needs for patients with endometrial cancer.

Aman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.

Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the goals of a study evaluating camu camu with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.

Mikkael A. Sekeres MD, MS, discusses the primary differences between imetelstat and other treatments available for patients with low- to intermediate-1 risk myelodysplastic syndromes.

Meredith McKean, MD, discusses a novel mRNA therapy for the treatment of solid tumors.

In an interview, Amrita Krishnan, MD, discussed several key advancements and challenges in the field of multiple myeloma.

Nausheen Ahmed, MD, discusses the guidelines for monitoring patients after receiving CAR T-cell therapy.

Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.

Matthew Hadfield, DO, discusses what community oncologists should know about immunotherapy toxicities.

Francis P. Worden, MD, discusses the background of a study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, including in those with BRAF-mutated, wild-type and BRAF untested tumors.

Timothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.

Moritz Fürstenau, MD, discussed a follow-up of the GAIA/CLL13 study exploring venetoclax combinations vs chemoimmunotherapy for the treatment of chronic lymphocytic leukemia.

Ali Duffens, MD, discusses the relative effectiveness of different detection modalities in identifying breast cancer recurrences.

Erin E. Hahn, PhD, MPH, discussed the findings and implications of a retrospective study exploring breast cancer surveillance in pre- and post-COVID periods.

Neeraj Agarwal, MD, discusses some of the unmet needs that exist in the prostate cancer space.

Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.

Mayuko Sakae, MD, discusses findings from research presented at the 2024 Multinational Association of Supportive Care in Cancer Annual Meeting on refractory pain in patients who have undergone a bone marrow transplant.

In an interview, Benjamin H. Lowentritt, MD, FACS, compared PSA response rates between apalutamide and enzalutamide in patients with metastatic castration-sensitive prostate cancer.

Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the lead up to the SENTRY trial and its potential impact on the treatment of myelofibrosis.

The FDA has granted 510(k) clearance to the SeCore™ CDx HLA A sequencing system as companion diagnostic for afamitresgene autoleucel in synovial sarcoma, paving the way for a first-of-its-kind solid tumor therapy.

In an interview, Timothy F. Cloughesy, MD, discussed the recent approval of vorasidenib in IDH-mutant gliomas and data from the phase 3 INDIGO trial.

In an interview with Targeted Oncology, Richard Lee, MD, discussed what integrative oncology encompasses and its significance in modern cancer care.

Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.